Blog
RSS FeedPosted by Michael Wonder on 07 Oct 2022
COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk
4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...
Posted by Michael Wonder on 15 Jul 2021
G-BA sees “considerable additional benefit” in two active ingredients - EU HTA analysis is coming
15 July 2021 - The Federal Joint Committee (G-BA) today certified two active ingredients with a "considerable additional benefit". It assigns ...
Posted by Michael Wonder on 05 Jul 2020
Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority
1 July 2020 - Informative comparative data are missing / resistance situation not sufficiently considered in approval studies. ...
Posted by Michael Wonder on 19 Dec 2016
Vertex announces German reimbursement agreement for Orkambi (lumacaftor with ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation
19 December 2016 - Vertex Pharmaceuticals today announced it has reached a pricing and reimbursement agreement for Orkambi (lumacaftor with ...
Posted by Michael Wonder on 17 Oct 2016
Sofosbuvir with velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications
17 October 2016 - Historical comparisons and considerations of individual study arms unsuitable for conclusions on the other research questions. ...
Posted by Michael Wonder on 17 Oct 2016
Emtricitabine/rilpivirine/tenofovir alafenamide in HIV: added benefit not proven
17 October 2016 - Research questions on adolescents not investigated/evidence on components not simply transferable to the combination. ...
Posted by Michael Wonder on 05 Oct 2016
Sitagliptin and sitagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional benefit compared to sulphonylurea plus metformin hydrochloride
4 October 2016 - For other questions, an additional benefit has not been established. ...
Posted by Michael Wonder on 05 Oct 2016
Saxagliptin and saxagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional clinical benefits still not there
4 October 2016 - Study evaluations unsuitable for statements about the positive or negative effects over comparative therapies. ...
Posted by Michael Wonder on 15 Aug 2016
Emtricitabine with tenofovir alafenamide fumarate in HIV infection: additional benefits not covered
15 August 2016 - Deviation from the appropriate comparator therapy/higher loss for certain patients. ...
Posted by Michael Wonder on 16 Jun 2016
Sacubitril with valsartan in heart failure: differentiated value added
16 June 2016 - Addendum results in a revised benefit assessment for patients with type 2 diabetes mellitus. ...
Posted by Michael Wonder on 06 Apr 2016
Genvoya in HIV: positive effects predominate in some adults, negative effects in others says Germany's IQWiG
1 April 2016 - The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the ...
Posted by Michael Wonder on 25 Nov 2015
Netupitant with palonosetron hydrochloride for the prevention of nausea and vomiting: added benefit not proven says IQWiG
16 November 2015 - According to the findings, an added clinical benefit is not proven in moderately emetogenic or in highly ...
Posted by Michael Wonder on 18 Nov 2015
Insulin degludec plus liraglutide: again no hint of added benefit in type 2 diabetes says IQWiG
16 November 2015 - The manufacturer presented no relevant data for the assessment of the added benefit of insulin degludec/liraglutide versus ...